Assembly Biosciences

ASMB

Biotech

Health Care

Pharma

Country

US

Industry

Health Care

Market Cap

Micro Cap

Num. Employees

68

IPO Date

Dec 17, 2010

Create Alert

ASMB

Country

US

Industry

Health Care

Biotech

Health Care

+1

Create Alert

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. The company is headquartered in South San Francisco, California and currently employs 68 full-time employees. The company went IPO on 2010-12-17. Its hepatitis B virus (HBV) pipeline includes potent, HBV core inhibitors in clinical development, which are designed to disrupt the virus replication cycle at several key points with a focus on achieving finite treatment and functional cures. Its HBV and hepatitis delta virus (HDV) pipeline also includes two complementary approaches: a viral entry inhibitor and an oral, liver-focused, interferon-alpha receptor agonist, with potential application for both HBV and as chronic suppressive therapy for HDV, which is associated with increased disease burden for HBV/HDV patients. The herpesvirus pipeline addresses two serious consequences associated with herpesvirus infections, high-recurrence genital herpes and transplant-associated herpesviruses. Its HBV and HDV programs include ABI-4334 (4334), ABI-5366 (5366), HBV/HDV inhibitor program, and others.